Fortress Biotech (NASDAQ:FBIO) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission [Yahoo! Finance]
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
Fortress Biotech (NASDAQ:FBIO) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.